PRKN and amyotrophic lateral sclerosis: Dexpramipexole (KNS-760704) and olesoxime (TR019622), compounds reported to target the mPTP 25 and assessed in phase II ALS trials 26, had no effect on parkin recruitment or mitochondrial form.